New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
16:41 EDTVVUSVIVUS reports Q4 EPS (56c), consensus (44c)
Reports Q4 revenue $1.97M, consensus $3.09M. The increase in net loss was primarily attributable to higher selling, general and administrative expenses related to commercialization activities for Qsymia. In Q4, the company recognized net product revenues of $2M from sales of Qsymia.
News For VVUS From The Last 14 Days
Check below for free stories on VVUS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 11, 2014
07:06 EDTVVUSVIVUS announces avanafil clinical data presentation
Subscribe for More Information
April 8, 2014
11:03 EDTVVUSPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use